RU2215528C2 - Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b - Google Patents
Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b Download PDFInfo
- Publication number
- RU2215528C2 RU2215528C2 RU2000109558/14A RU2000109558A RU2215528C2 RU 2215528 C2 RU2215528 C2 RU 2215528C2 RU 2000109558/14 A RU2000109558/14 A RU 2000109558/14A RU 2000109558 A RU2000109558 A RU 2000109558A RU 2215528 C2 RU2215528 C2 RU 2215528C2
- Authority
- RU
- Russia
- Prior art keywords
- combination
- methylpiperazin
- component
- tetrahydro
- naphthyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract 12
- 239000004031 partial agonist Substances 0.000 title claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 239000012453 solvate Substances 0.000 claims abstract 5
- 208000019022 Mood disease Diseases 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 8
- -1 (R) -5-carbamoyl-3- (N-cyclopentyl-N-isobutylamino) -8-fluoro-3,4-dihydro-2H-1-benzopyran Chemical compound 0.000 claims 4
- 239000002585 base Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- IHDRUIHIJWCTIY-JOCHJYFZSA-N n-[(2r)-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(C)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 IHDRUIHIJWCTIY-JOCHJYFZSA-N 0.000 claims 3
- 239000003727 serotonin 1A antagonist Substances 0.000 claims 3
- IAFNMDAKUNVLSN-GFCCVEGCSA-N (3r)-3-[cyclobutyl(propyl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CCCN([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCC1 IAFNMDAKUNVLSN-GFCCVEGCSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- XCSBGPAPGUIEFO-OAQYLSRUSA-N n-[(2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 XCSBGPAPGUIEFO-OAQYLSRUSA-N 0.000 claims 2
- HWSWMVFTXFBDRW-JOCHJYFZSA-N n-[(2r)-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 HWSWMVFTXFBDRW-JOCHJYFZSA-N 0.000 claims 2
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 claims 2
- OPQNWTZQVSEVAP-OAQYLSRUSA-N (2R)-5-methoxy-8-(4-methylpiperazin-1-yl)-N-[4-(morpholine-4-carbonyl)phenyl]-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound C([C@H](CC=12)C(=O)NC=3C=CC(=CC=3)C(=O)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 OPQNWTZQVSEVAP-OAQYLSRUSA-N 0.000 claims 1
- AOSCUPVQGZCMHA-GFCCVEGCSA-N (3r)-3-[cyclobutyl(propan-2-yl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CC(C)N([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCC1 AOSCUPVQGZCMHA-GFCCVEGCSA-N 0.000 claims 1
- JBRZRUJXYGBTBQ-CQSZACIVSA-N (3r)-3-[cyclohexyl(propyl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CCCN([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCCCC1 JBRZRUJXYGBTBQ-CQSZACIVSA-N 0.000 claims 1
- PBDYMMOBUALQNA-LLVKDONJSA-N (3r)-3-[tert-butyl(propyl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound C1=CC(C(N)=O)=C2C[C@@H](N(CCC)C(C)(C)C)COC2=C1F PBDYMMOBUALQNA-LLVKDONJSA-N 0.000 claims 1
- HDRGYUKRRPGJKR-LLVKDONJSA-N (3r)-8-fluoro-3-[propan-2-yl(propyl)amino]-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound C1=CC(C(N)=O)=C2C[C@@H](N(C(C)C)CCC)COC2=C1F HDRGYUKRRPGJKR-LLVKDONJSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- OOEQHHKVTDYZTD-OAQYLSRUSA-N 4-morpholin-4-yl-n-[(2r)-8-piperazin-1-yl-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide Chemical compound C([C@H](CC1=2)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC1=CC=CC=2N1CCNCC1 OOEQHHKVTDYZTD-OAQYLSRUSA-N 0.000 claims 1
- NPFRXRWSLBQFJT-FQEVSTJZSA-N 4-n,4-n-dimethyl-1-n-[(3s)-8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2h-chromen-3-yl]benzene-1,4-dicarboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C(=O)N[C@H]1CC2=C(N3CCN(C)CC3)C=CC(C)=C2OC1 NPFRXRWSLBQFJT-FQEVSTJZSA-N 0.000 claims 1
- GGWPSJWVARDUIR-UHFFFAOYSA-N 8-methoxy-5-(4-methylpiperazin-1-yl)-n-(4-morpholin-4-ylphenyl)-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1=2CC(C(=O)NC=3C=CC(=CC=3)N3CCOCC3)COC=2C(OC)=CC=C1N1CCN(C)CC1 GGWPSJWVARDUIR-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- LWFVPTYGZMOPBW-UHUGOGIASA-N CCCN(C1CCCC1)C2CC3=C(C=CC(=C3O[C@H]2C(=O)N)F)C Chemical compound CCCN(C1CCCC1)C2CC3=C(C=CC(=C3O[C@H]2C(=O)N)F)C LWFVPTYGZMOPBW-UHUGOGIASA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- BSBVBFLNLYJFBZ-QGZVFWFLSA-N n-[(2r)-5-bromo-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(Br)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)C(F)(F)F)CC2 BSBVBFLNLYJFBZ-QGZVFWFLSA-N 0.000 claims 1
- BYJYPZAHTUBRNT-HXUWFJFHSA-N n-[(2r)-5-bromo-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(Br)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 BYJYPZAHTUBRNT-HXUWFJFHSA-N 0.000 claims 1
- OXZHFWAHGKDGDI-LJQANCHMSA-N n-[(2r)-5-bromo-8-piperazin-1-yl-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(Br)=CC=C2N1CCNCC1 OXZHFWAHGKDGDI-LJQANCHMSA-N 0.000 claims 1
- BEEWOAIWRLZBGZ-HSZRJFAPSA-N n-[(2r)-5-ethyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(CC)=CC=C2N1CCN(C)CC1 BEEWOAIWRLZBGZ-HSZRJFAPSA-N 0.000 claims 1
- WZMSJJIAEOODBC-JOCHJYFZSA-N n-[(2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-(morpholine-4-carbonyl)benzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)C(=O)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 WZMSJJIAEOODBC-JOCHJYFZSA-N 0.000 claims 1
- FTCLFWOUOUOQEH-HSZRJFAPSA-N n-[(2r)-8-(4-ethylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(CC)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 FTCLFWOUOUOQEH-HSZRJFAPSA-N 0.000 claims 1
- VAAMBBBNNWFJHZ-FQEVSTJZSA-N n-[(3s)-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2h-chromen-3-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CO2 VAAMBBBNNWFJHZ-FQEVSTJZSA-N 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004000 serotonin 1B antagonist Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703374-0 | 1997-09-18 | ||
| SE9703374A SE9703374D0 (sv) | 1997-09-18 | 1997-09-18 | A new combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000109558A RU2000109558A (ru) | 2002-02-10 |
| RU2215528C2 true RU2215528C2 (ru) | 2003-11-10 |
Family
ID=20408294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000109558/14A RU2215528C2 (ru) | 1997-09-18 | 1998-09-09 | Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6159972A (https=) |
| EP (1) | EP1021183B1 (https=) |
| JP (1) | JP2001516717A (https=) |
| KR (1) | KR20010024075A (https=) |
| CN (1) | CN1182847C (https=) |
| AR (1) | AR015447A1 (https=) |
| AT (1) | ATE261728T1 (https=) |
| AU (1) | AU752718B2 (https=) |
| BR (1) | BR9812234A (https=) |
| CA (1) | CA2302383A1 (https=) |
| DE (1) | DE69822490T2 (https=) |
| DK (1) | DK1021183T3 (https=) |
| EE (1) | EE04142B1 (https=) |
| ES (1) | ES2216307T3 (https=) |
| HU (1) | HUP0100401A3 (https=) |
| IL (1) | IL134774A0 (https=) |
| IS (1) | IS5408A (https=) |
| MY (1) | MY116281A (https=) |
| NO (1) | NO20001398L (https=) |
| NZ (1) | NZ503174A (https=) |
| PL (1) | PL339370A1 (https=) |
| PT (1) | PT1021183E (https=) |
| RU (1) | RU2215528C2 (https=) |
| SE (1) | SE9703374D0 (https=) |
| SK (1) | SK2842000A3 (https=) |
| TR (1) | TR200000734T2 (https=) |
| TW (1) | TW568786B (https=) |
| WO (1) | WO1999013876A1 (https=) |
| ZA (1) | ZA987810B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601110D0 (sv) | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| WO2002066454A1 (fr) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| ATE424825T1 (de) * | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
| USD969016S1 (en) | 2021-06-28 | 2022-11-08 | Koninklijke Asscher Diamant Maatschappij B.V. | Rose oval diamond article |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2059623C1 (ru) * | 1989-02-02 | 1996-05-10 | Яманути Фармасьютикал Ко., Лтд. | Тетрагидробензимидазольное производное или его фармацевтически приемлемая соль и фармацевтическая композиция на его основе, проявляющая активность 5-ht3-антагониста |
| WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
| RU2077535C1 (ru) * | 1991-09-18 | 1997-04-20 | Глэксо Груп Лимитед | Производные бензанилида, способ их получения и фармацевтическая композиция, проявляющая антагонизм к 5-htid рецепторам |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| FI961247A0 (fi) * | 1996-03-18 | 1996-03-18 | Finnish Peroxides Ab Oy | Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
-
1997
- 1997-09-18 SE SE9703374A patent/SE9703374D0/xx unknown
-
1998
- 1998-08-27 ZA ZA987810A patent/ZA987810B/xx unknown
- 1998-08-29 TW TW087114345A patent/TW568786B/zh not_active IP Right Cessation
- 1998-09-09 US US09/171,581 patent/US6159972A/en not_active Expired - Fee Related
- 1998-09-09 CN CNB988112493A patent/CN1182847C/zh not_active Expired - Fee Related
- 1998-09-09 ES ES98944374T patent/ES2216307T3/es not_active Expired - Lifetime
- 1998-09-09 AT AT98944374T patent/ATE261728T1/de not_active IP Right Cessation
- 1998-09-09 PT PT98944374T patent/PT1021183E/pt unknown
- 1998-09-09 RU RU2000109558/14A patent/RU2215528C2/ru not_active IP Right Cessation
- 1998-09-09 NZ NZ503174A patent/NZ503174A/en unknown
- 1998-09-09 BR BR9812234-7A patent/BR9812234A/pt not_active IP Right Cessation
- 1998-09-09 EE EEP200000143A patent/EE04142B1/xx not_active IP Right Cessation
- 1998-09-09 HU HU0100401A patent/HUP0100401A3/hu unknown
- 1998-09-09 CA CA002302383A patent/CA2302383A1/en not_active Abandoned
- 1998-09-09 KR KR1020007002821A patent/KR20010024075A/ko not_active Ceased
- 1998-09-09 SK SK284-2000A patent/SK2842000A3/sk unknown
- 1998-09-09 JP JP2000511498A patent/JP2001516717A/ja active Pending
- 1998-09-09 DE DE69822490T patent/DE69822490T2/de not_active Expired - Fee Related
- 1998-09-09 PL PL98339370A patent/PL339370A1/xx unknown
- 1998-09-09 EP EP98944374A patent/EP1021183B1/en not_active Expired - Lifetime
- 1998-09-09 AU AU91929/98A patent/AU752718B2/en not_active Ceased
- 1998-09-09 TR TR2000/00734T patent/TR200000734T2/xx unknown
- 1998-09-09 WO PCT/SE1998/001600 patent/WO1999013876A1/en not_active Ceased
- 1998-09-09 IL IL13477498A patent/IL134774A0/xx unknown
- 1998-09-09 DK DK98944374T patent/DK1021183T3/da active
- 1998-09-16 MY MYPI98004226A patent/MY116281A/en unknown
- 1998-09-17 AR ARP980104633A patent/AR015447A1/es unknown
-
2000
- 2000-03-15 IS IS5408A patent/IS5408A/is unknown
- 2000-03-17 NO NO20001398A patent/NO20001398L/no not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2059623C1 (ru) * | 1989-02-02 | 1996-05-10 | Яманути Фармасьютикал Ко., Лтд. | Тетрагидробензимидазольное производное или его фармацевтически приемлемая соль и фармацевтическая композиция на его основе, проявляющая активность 5-ht3-антагониста |
| RU2077535C1 (ru) * | 1991-09-18 | 1997-04-20 | Глэксо Груп Лимитед | Производные бензанилида, способ их получения и фармацевтическая композиция, проявляющая антагонизм к 5-htid рецепторам |
| WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2214824C2 (ru) | Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b | |
| RU2000109563A (ru) | Комбинация обратного поглощения 5-нт селективного антагониста или частичного агониста н5-нт1b | |
| JP2001516718A5 (https=) | ||
| JP2001516719A5 (https=) | ||
| RU2407532C9 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| RU2004131641A (ru) | Новые соединения | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| BG108420A (en) | New indole derivatives with 5-ht6 receptor affinity | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| JP2004517843A5 (https=) | ||
| RU97119427A (ru) | Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом | |
| RU2007115161A (ru) | Новые производные фталазинона в качестве ингибиторов киназы аврора-а | |
| CN1681505A (zh) | 用于治疗白血病的а ) N－{ 5－[ 4－( 4－甲基－哌嗪－1－基－甲基)－苯甲酰氨基]－2－甲基苯基}－4－( 3－吡啶基 ) －2－嘧啶－胺和b )组蛋白脱乙酰基酶抑制剂的组合 | |
| RU2215528C2 (ru) | Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b | |
| AR013503A1 (es) | Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion | |
| HUP0203716A2 (hu) | Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| RU2000109558A (ru) | Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| BR0308982A (pt) | Combinações de epinastina, beladona e pseudoefedrina como novas formulações farmacêuticas | |
| JP2001516717A5 (https=) | ||
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20050910 |